A Study of Orforglipron (LY3502970) to Compare a Single Capsule and Multiple Capsules in Healthy Participants
← catalyst calendarSponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Randomized · None · Basic science
Enrollment
86actual
Sites
3
Country
Japan
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-12-13 | actual | When the study began enrolling |
| Primary completion | 2025-06-09 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-06-09 | actual | The whole study's end, after follow-up |
| First posted | 2024-11-18 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-06-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy
Intervention
- Drug: Orforglipron — also filed as LY3502970
Primary outcomes
what the primary-completion date above is the date OFPharmacokinetics (PK): Steady-state Area Under the Concentration Versus Time Curve (AUC) of Orforglipron (Fasted State)
measured Week 3 Through Week 16
PK: Steady-state Maximum Concentration (Cmax) of Orforglipron (Fasted State)
measured Week 3 Through Week 16
PK: Steady-state AUC of Orforglipron (Fed State)
measured Week 3 Through Week 16
PK: Steady-state Cmax of Orforglipron (Fed State)
measured Week 3 Through Week 16
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed